A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity
Public ClinicalTrials.gov record NCT07310901. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Dose-Range Finding Study of the Efficacy, Safety, and Pharmacokinetics of CRB-913 in Participants With Obesity With a Single Cohort Open-label Exploratory Pharmacokinetic Lead-In
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will assess the safety of the investigational drug CRB-913 and how it is processed in the body. The study has two parts: Part 1 will measure drug levels in healthy adults after taking CRB-913 tablets, and Part 2 will compare three doses of CRB-913 with placebo to evaluate safety, effects on body weight, and drug levels in the blood. Part 2 is blinded, meaning participants, study doctors, and the sponsor will not know which treatment is given. Participants in Part 2 will take study treatment for 12 weeks and will be followed for 28 days after treatment ends.
Study identification
- NCT ID
- NCT07310901
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 254 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 4, 2025 (Actual)
- Primary completion
- Aug 3, 2026 (Actual)
- Completion
- Aug 3, 2026 (Actual)
- Last update posted
- Oct 9, 2026
2025 – 2026
United States locations
- U.S. sites
- 15
- U.S. states
- 10
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Central Alabama Research | Birmingham | Alabama | 35209 | — |
| Arizona Clinical Trials | Chandler | Arizona | 85225 | — |
| Prospective Research Innovations | Rancho Cucamonga | California | 91730 | — |
| Accel Research Sites | DeLand | Florida | 32720 | — |
| Tampa Bay Medical Research | Largo | Florida | 33761 | — |
| Quotient Sciences | Miami | Florida | 33126 | — |
| Louisville Metabolic and Atherosclerosis Research Center | Louisville | Kentucky | 40213 | — |
| Alliance Clinical | Las Vegas | Nevada | 89109 | — |
| Neurobehavioral Research | Cedarhurst | New York | 11516 | — |
| Rochester Clinical Research | Rochester | New York | 14609 | — |
| Lucas Research | Morehead City | North Carolina | 28557 | — |
| Medpace Clinical Pharmacology | Cincinnati | Ohio | 45227 | — |
| Velocity Clinical Research | Cleveland | Ohio | 44122 | — |
| Velocity Clinical Research | Dallas | Texas | 75230 | — |
| Flourish Research | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07310901, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 9, 2026 · Synced Oct 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07310901 live on ClinicalTrials.gov.